Results 271 to 280 of about 9,263,948 (394)

Molestia de Hodgkin Hodgkin's disease

Memorias do Instituto Oswaldo Cruz, 1929
José Guilherme Lacorte
doaj   +1 more source

A Comprehensive Review of Kimura Disease. [PDF]

Head Neck Pathol
Lagerstrom IT, Danielson DT, Muir JM, Foss RD, Auerbach A, Aguilera NS.   +5 more
europepmc   +1 more source

Atypical hodgkin and reed-sternberg cells in peripheral blood of a patient with advanced stage of Hodgkin's disease - a case report

, 2003
Rajko Milošević, Milica Čolović, Vesna Čemerikić‐Martinović, Nataša Čolović, Marina Bogunović   +4 more
openalex   +2 more sources

Final Results From a Large, Non‐Interventional, Phase 4 Study of Ruxolitinib for the Treatment of Myelofibrosis in Clinical Routine

European Journal of Haematology, EarlyView.
ABSTRACT JAKoMo was a long‐term, multicenter, non‐interventional study observing the efficacy, safety, and quality of life (QOL) effects of ruxolitinib (RUX), managed per clinical routine at investigator discretion, for treatment of 943 patients with myelofibrosis (MF) in 122 German centers.
Steffen Koschmieder, Susanne Isfort, Clemens Schulte, Lutz Jacobasch, Thomas Geer, Marcel Reiser, Michael Koenigsmann, Bernhard Heinrich, Jürgen Wehmeyer, Eyck von der Heyde, Hans Tesch, Benedikt Gröschl, Petra Bachhuber, Susanne Großer, Michael Koehler, Heike L. Pahl   +15 more
wiley   +1 more source

Current State of AIDS-Related Malignant Lymphoma. [PDF]

Viruses
Okada S, Hagiwara S, Nagai H.
europepmc   +1 more source

Machine Learning for Prediction of High‐Risk Hospitalizations in Lymphoma Patients: A Danish Population‐Based Study

European Journal of Haematology, EarlyView.
ABSTRACT Objective Infections are a leading cause of hospitalization in patients treated for lymphoma and can be life‐threatening. This study developed a machine learning (ML)‐based risk stratification method to classify infection‐related hospitalizations (IRH) into serious‐IRH (S‐IRH) and non‐serious‐IRH (NS‐IRH).
Alexander Djupnes Fuglkjaer, Deniz Kenan Kilic, Mathias Holmsgaard Eskesen, Mikkel Runason Simonsen, Laurids Østergaard Poulsen, Carsten Utoft Niemann, Paw Jensen, Kirstine Kobberøe Søgaard, Mikkel Werling, Frederik Christensen, Izabela Ewa Nielsen, Tarec Christoffer El‐Galaly   +11 more
wiley   +1 more source

The Efficacy of Polatuzumab Vedotin Targeting CD79B in the Treatment of Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis. [PDF]

Int J Mol Sci
Alshehri S, Khan B, Khan NU, Unar A.
europepmc   +1 more source

Incremental immunogenicity of multiple doses of SARS‐CoV‐2 vaccination in patients with haematological malignancies

British Journal of Haematology, EarlyView.
Abi Vijenthira, Sita Bhella, Katrina Hueniken, Allison M. Wilkin, Michael Sebag, Peng Wang, Lisa K. Hicks, Annette E. Hay, Sarit Assouline, Amaris Balitsky, Graeme Fraser, Joy Mangel, Carolyn Owen, Anthony Reiman, Laurie Sehn, Heather Sutherland, Corey Arnold, Tamara Leite, Erinn McCarthy, Angela Crawley, Curtis Cooper, Marc‐Andre Langlois, C. Arianne Buchan, VIP Study Investigators   +23 more
wiley   +1 more source

Rare dysfunctional SCN2A variants are associated with malformation of cortical development

Epilepsia, Volume 66, Issue 3, Page 914-928, March 2025.
Abstract Objective SCN2A encodes the voltage‐gated sodium (Na+) channel α subunit NaV1.2, which is important for the generation and forward and back propagation of action potentials in neurons. Genetic variants in SCN2A are associated with a spectrum of neurodevelopmental disorders.
Jérôme Clatot, Christopher H. Thompson, Susan Sotardi, Jinan Jiang, Marina Trivisano, Simona Balestrini, D. Isum Ward, Natalie Ginn, Brunetta Guaragni, Laura Malerba, Angeliki Vakrinou, Mia Sherer, Ingo Helbig, Ala Somarowthu, Sanjay M. Sisodiya, Roy Ben‐Shalom, Renzo Guerrini, Nicola Specchio, Alfred L. George Jr, Ethan M. Goldberg   +19 more
wiley   +1 more source

A Rare Case of Hodgkin Lymphoma With Isolated Epitrochlear Lymphadenopathy. Our Experience and Main Differential Diagnosis. [PDF]

Case Rep Med
Cea L, Santucci D, Bernetti C, Nibid L, Tomarchio V, Bruno A, Beomonte Zobel B, Grasso RF, Faiella E.   +8 more
europepmc   +1 more source